Literature DB >> 24610870

Aerosol interleukin-2 induces natural killer cell proliferation in the lung and combination therapy improves the survival of mice with osteosarcoma lung metastasis.

Sergei R Guma1, Dean A Lee, Yu Ling, Nancy Gordon, Eugenie S Kleinerman.   

Abstract

BACKGROUND: We have previously shown that aerosol interleukin-2 (IL-2) increased the number of intravenously injected human natural killer (NK) cells in the lungs. In this study we investigated whether this increase was secondary to NK cell proliferation and determined the site of the proliferation.
MATERIALS AND METHODS: Nude mice with osteosarcoma lung metastases were injected with NK cells and treated with aerosol IL-2 or aerosol PBS. BrdU was injected prior to euthanasia to identify proliferating NK cells. The percentage of proliferating NK cells in the lung, bone marrow, spleen, and liver was determined using flow cytometry. Survival studies for mice with osteosarcoma lung metastasis treated with aerosol PBS, aerosol IL-2 alone, aerosol PBS plus NK cells, and aerosol IL-2 plus NK cells were also performed.
RESULTS: Treatment with aerosol IL-2 induced the proliferation of injected NK cells in the lung. Aerosol IL-2 did not increase the proliferation of NK cells in the spleen and liver. Treatment with aerosol IL-2 and aerosol IL-2 plus NK cells increased the overall survival of mice with osteosarcoma lung metastasis.
CONCLUSION: Aerosol IL-2 increases lung NK cell numbers by stimulating local NK cell proliferation. Aerosol IL-2's effect on NK cell proliferation is organ specific, which makes it ideal for the specific targeting of lung metastasis. Aerosol IL-2 plus NK cell therapy induced metastatic regression and increased overall survival demonstrating the potential of this therapeutic approach for patients with osteosarcoma.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  aerosol interleukin-2; cytokines; immunotherapy; lung metastasis; natural killer cells; osteosarcoma

Mesh:

Substances:

Year:  2014        PMID: 24610870      PMCID: PMC4144337          DOI: 10.1002/pbc.25019

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  37 in total

1.  Characteristics of NK cell migration early after vaccinia infection.

Authors:  Martin Prlic; James Gibbs; Stephen C Jameson
Journal:  J Immunol       Date:  2005-08-15       Impact factor: 5.422

2.  An economical adaptation of the RosetteSep procedure for NK cell enrichment from whole blood, and its use with liquid nitrogen stored peripheral blood mononuclear cells.

Authors:  Hilary S Warren; Purna M Rana
Journal:  J Immunol Methods       Date:  2003-09       Impact factor: 2.303

3.  Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors.

Authors:  Sebastian Giebel; Franco Locatelli; Teresa Lamparelli; Andrea Velardi; Stella Davies; Guido Frumento; Rita Maccario; Federico Bonetti; Jerzy Wojnar; Miryam Martinetti; Francesco Frassoni; Giovanna Giorgiani; Andrea Bacigalupo; Jerzy Holowiecki
Journal:  Blood       Date:  2003-04-10       Impact factor: 22.113

4.  A defined donor activating natural killer cell receptor genotype protects against leukemic relapse after related HLA-identical hematopoietic stem cell transplantation.

Authors:  S Verheyden; R Schots; W Duquet; C Demanet
Journal:  Leukemia       Date:  2005-08       Impact factor: 11.528

5.  Mifamurtide for high-grade, resectable, nonmetastatic osteosarcoma following surgical resection: a cost-effectiveness analysis.

Authors:  Sukhvinder Johal; Stephen Ralston; Christopher Knight
Journal:  Value Health       Date:  2013-10-03       Impact factor: 5.725

6.  Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation.

Authors:  Heather J Symons; M Sue Leffell; Nancy D Rossiter; Marianna Zahurak; Richard J Jones; Ephraim J Fuchs
Journal:  Biol Blood Marrow Transplant       Date:  2009-12-02       Impact factor: 5.742

7.  Impact of natural killer cell dose and donor killer-cell immunoglobulin-like receptor (KIR) genotype on outcome following human leucocyte antigen-identical haematopoietic stem cell transplantation.

Authors:  J Clausen; D Wolf; A L Petzer; E Gunsilius; P Schumacher; B Kircher; G Gastl; D Nachbaur
Journal:  Clin Exp Immunol       Date:  2007-06       Impact factor: 4.330

8.  Chemokine-mediated recruitment of NK cells is a critical host defense mechanism in invasive aspergillosis.

Authors:  Brad E Morrison; Stacy J Park; Jill M Mooney; Borna Mehrad
Journal:  J Clin Invest       Date:  2003-12       Impact factor: 14.808

9.  Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.

Authors:  Paul A Meyers; Cindy L Schwartz; Mark D Krailo; John H Healey; Mark L Bernstein; Donna Betcher; William S Ferguson; Mark C Gebhardt; Allen M Goorin; Michael Harris; Eugenie Kleinerman; Michael P Link; Helen Nadel; Michael Nieder; Gene P Siegal; Michael A Weiner; Robert J Wells; Richard B Womer; Holcombe E Grier
Journal:  J Clin Oncol       Date:  2008-02-01       Impact factor: 44.544

10.  CCR2 defines a distinct population of NK cells and mediates their migration during influenza virus infection in mice.

Authors:  Mary J G van Helden; Dietmar M W Zaiss; Alice J A M Sijts
Journal:  PLoS One       Date:  2012-12-13       Impact factor: 3.240

View more
  13 in total

Review 1.  Pulmonary delivery of nanoparticle chemotherapy for the treatment of lung cancers: challenges and opportunities.

Authors:  Sharad Mangal; Wei Gao; Tonglei Li; Qi Tony Zhou
Journal:  Acta Pharmacol Sin       Date:  2017-05-01       Impact factor: 6.150

2.  Effect of entinostat on NK cell-mediated cytotoxicity against osteosarcoma cells and osteosarcoma lung metastasis.

Authors:  Simin Kiany; Gangxiong Huang; Eugenie S Kleinerman
Journal:  Oncoimmunology       Date:  2017-07-11       Impact factor: 8.110

3.  MicroRNA-126 enhances the sensitivity of osteosarcoma cells to cisplatin and methotrexate.

Authors:  Liangdong Jiang; Aiyong He; Xiaojie He; Cheng Tao
Journal:  Oncol Lett       Date:  2015-10-09       Impact factor: 2.967

Review 4.  Future directions in the treatment of osteosarcoma.

Authors:  Michael W Bishop; Katherine A Janeway; Richard Gorlick
Journal:  Curr Opin Pediatr       Date:  2016-02       Impact factor: 2.856

Review 5.  Targeting tumor metastases: Drug delivery mechanisms and technologies.

Authors:  Vidya Ganapathy; Prabhas V Moghe; Charles M Roth
Journal:  J Control Release       Date:  2015-09-25       Impact factor: 9.776

Review 6.  The Histone Deacetylase Inhibitor Entinostat/Syndax 275 in Osteosarcoma.

Authors:  Simin Kiany; Douglas Harrison; Nancy Gordon
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

Review 7.  Natural Killer Cell Immunotherapy for Osteosarcoma.

Authors:  Brian P Tullius; Buhvana A Setty; Dean A Lee
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

8.  Strategies and developments of immunotherapies in osteosarcoma.

Authors:  Jia Wan; Xianghong Zhang; Tang Liu; Xiangsheng Zhang
Journal:  Oncol Lett       Date:  2015-11-24       Impact factor: 2.967

Review 9.  Bone Sarcomas in Pediatrics: Progress in Our Understanding of Tumor Biology and Implications for Therapy.

Authors:  Rocio K Rivera-Valentin; Limin Zhu; Dennis P M Hughes
Journal:  Paediatr Drugs       Date:  2015-08       Impact factor: 3.022

Review 10.  Innate Immune Cells: A Potential and Promising Cell Population for Treating Osteosarcoma.

Authors:  Zenan Wang; Zhan Wang; Binghao Li; Shengdong Wang; Tao Chen; Zhaoming Ye
Journal:  Front Immunol       Date:  2019-05-16       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.